RxDoctor Payments Data

Debra Krieg, MD

Family Medicine · Fort Worth, TXNPI 1750373106

Payments from drug & device makers

$4,910in general payments, 2019–2025

Across 311 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$830
  • AstraZeneca$567
  • Lilly USA, LLC$453
  • Pfizer$338
  • Kowa Pharmaceuticals America, Inc.$194
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$4,86099%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,910 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$58,288
Medicare patients
200
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$107,715
FarxigaDapagliflozin Propanediol80$72,850
JardianceEmpagliflozin46$64,317
MounjaroTirzepatide29$59,950
TrulicityDulaglutide26$41,233
EliquisApixaban21$18,917
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,017
PaxlovidNirmatrelvir/Ritonavir13$2,694
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide61$2,628
SynthroidLevothyroxine Sodium24$2,547
Levothyroxine Sodium211$2,239
Estradiol30$1,977
Rosuvastatin Calcium189$1,841
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,835
Atorvastatin Calcium232$1,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,205$107,71571 claims
Lilly USA, LLCMounjaro, Trulicity$453$101,18355 claims
AstraZenecaFarxiga$567$72,85080 claims
Boehringer IngelheimJardiance$113$64,31746 claims
PfizerEliquis, Paxlovid$338$21,61134 claims
GSKTrelegy Ellipta$79$7,01711 claims
AbbVieSynthroid$830$2,54724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →